AstraZeneca divests rights to Seroquel and Seroquel XR in Europe and Russia
30 October 2019 07:00 GMT AstraZeneca divests rights to Seroquel and Seroquel XR in Europe and Russia Sale to Cheplapharm supports AstraZeneca's focus on main therapy areas AstraZeneca has agreed the sale and licence of the commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in Europe and Russia to Cheplapharm Arzneimittel GmbH (Cheplapharm). Seroquel and Seroquel XR, used primarily to treat schizophrenia and bipolar disorder, have lost their compound patent protection in Europe and Russia. Ruud Dobber,